Stattin P - Search Results

1

Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

Loeb S, Berglund A, Stattin P. Loeb S, et al. Among authors: stattin p. J Urol. 2013 Nov;190(5):1742-9. doi: 10.1016/j.juro.2013.05.054. Epub 2013 May 30. J Urol. 2013. PMID: 23727309

2

Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients.

Stattin P, Damber JE, Modig H, Bergh A. Stattin P, et al. Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):885-9. doi: 10.1016/0360-3016(96)00134-4. Int J Radiat Oncol Biol Phys. 1996. PMID: 8751397

3

p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.

Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE. Stattin P, et al. Eur Urol. 1996;30(1):65-72. doi: 10.1159/000474147. Eur Urol. 1996. PMID: 8854070

4

Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.

Stattin P, Damber JE, Karlberg L, Bergh A. Stattin P, et al. J Urol. 1997 Jan;157(1):219-22. J Urol. 1997. PMID: 8976256

5

Prognostic factors in prostate cancer.

Stattin P. Stattin P. Scand J Urol Nephrol Suppl. 1997;185:1-46. Scand J Urol Nephrol Suppl. 1997. PMID: 9249905

6

Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.

Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE. Stattin P, et al. Eur Urol. 1997;32(4):404-9. Eur Urol. 1997. PMID: 9412796 Clinical Trial.

7

Evaluation of prognostic factors in prostate cancer with partial least squares analysis.

Wikström P, Wikström P, Lissbrant IF, Bergh A, Damber JE, Stattin P. Wikström P, et al. Among authors: stattin p. Scand J Urol Nephrol. 2000 Aug;34(4):252-6. doi: 10.1080/003655900750041988. Scand J Urol Nephrol. 2000. PMID: 11095083

8

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Stattin P, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7. doi: 10.1093/jnci/92.23.1910. J Natl Cancer Inst. 2000. PMID: 11106682

9

Leptin is associated with increased prostate cancer risk: a nested case-referent study.

Stattin P, Söderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, Olsson T. Stattin P, et al. J Clin Endocrinol Metab. 2001 Mar;86(3):1341-5. doi: 10.1210/jcem.86.3.7328. J Clin Endocrinol Metab. 2001. PMID: 11238530

10

Plasma prolactin and prostate cancer risk: A prospective study.

Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R. Stattin P, et al. Int J Cancer. 2001 May 1;92(3):463-5. doi: 10.1002/ijc.1191. Int J Cancer. 2001. PMID: 11291087 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results